Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Research & Development (2022 - 2024)

Adial Pharmaceuticals' Research & Development history spans 3 years, with the latest figure at $730793.0 for Q4 2024.

  • For Q4 2024, Research & Development rose 176.36% year-over-year to $730793.0; the TTM value through Dec 2024 reached $3.2 million, up 154.86%, while the annual FY2025 figure was $2.6 million, 18.88% down from the prior year.
  • Research & Development for Q4 2024 was $730793.0 at Adial Pharmaceuticals, down from $1.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $1.0 million in Q3 2024 and bottomed at -$22072.0 in Q4 2022.
  • The 3-year median for Research & Development is $525309.5 (2022), against an average of $537217.6.
  • The largest YoY upside for Research & Development was 1298.07% in 2023 against a maximum downside of 70.24% in 2023.
  • A 3-year view of Research & Development shows it stood at -$22072.0 in 2022, then surged by 1298.07% to $264437.0 in 2023, then skyrocketed by 176.36% to $730793.0 in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Research & Development are $730793.0 (Q4 2024), $1.0 million (Q3 2024), and $1.0 million (Q2 2024).